CSL CEO on Results, Global Business Outlook

CSL CEO on Results, Global Business Outlook Play

Aug. 14 (Bloomberg) -- Paul Perreault, chief executive officer of CSL Ltd., the world’s second-biggest maker of blood-derived therapies, talks about the company's financial performance and business outlook. CSL, reported a 19 percent jump in annual profit, boosted by demand in the U.S. and Europe for Hizentra, an infection-fighting infusion. Perreault speaks with Susan Li on Bloomberg Television's "First Up." (Source: Bloomberg)

  • On Air Now

    Street Smart with Trish Regan Watch Now

  • Next

    Taking Stock with Pimm Fox

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus